Among these therapeutic agents, crizotinib, a small-molecule tyrosine-kinase inhibitor that targets ALK, ROS1, and MET, was the first to be approved by the US Food and Drug Administration in 2011 for first-line treatment of metastatic NSCLC with ALK rearrangements [58]. Here, ROS1 is linked to non-small cell lung carcinoma.